Beck Capital Management’s Charles River Laboratories CRL Stock Holding History

Beck Capital Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,530	Closed	-$217K	–	100
2019 Q2	$217K	Sell	1,530 -415	-21%	-$56.3K	0.11%	89
2019 Q1	$282K	Buy	+1,945	New	+$256K	0.13%	87
2018 Q1	–	Sell	-2,865	Closed	-$314K	–	113
2017 Q4	$314K	Sell	2,865 -1,350	-32%	-$147K	0.14%	89
2017 Q3	$455K	Sell	4,215 -2,464	-37%	-$253K	0.22%	78
2017 Q2	$672K	Buy	+6,679	New	+$615K	0.35%	64

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Beck Capital Management's CRL Position: Q3 2019 in Review

Beck Capital Management sold out of Charles River Laboratories (CRL) in Q3 2019, closing a stake of 1,530 shares — an estimated $217K sold.

Beck Capital Management first reported a position in CRL in Q2 2017 and held it in 5 quarters. The position peaked at $672K in Q2 2017. 396 funds tracked by Wall St. Rank hold CRL as of Q3 2019.

Beck Capital Management reported no remaining Charles River Laboratories position as of Q3 2019 after selling out during the quarter.
Beck Capital Management sold 1,530 Charles River Laboratories shares in Q3 2019, an estimated $217K.
Beck Capital Management first reported a position in Charles River Laboratories in Q2 2017 and held it in 5 quarters.
Beck Capital Management's Charles River Laboratories position peaked at $672K in Q2 2017.
396 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2019.

Based on Beck Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.